Agilent Technologies, Inc. (LON:0HAV)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 23.62B +3.8% |
| Revenue (ttm) | 5.15B +8.1% |
| Net Income | 940.29M +2.5% |
| EPS | 3.30 +3.9% |
| Shares Out | n/a |
| PE Ratio | 25.12 |
| Forward PE | 18.36 |
| Dividend | 0.75 (0.66%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 799 |
| Average Volume | 1,453 |
| Open | 110.80 |
| Previous Close | 113.20 |
| Day's Range | 110.80 - 114.15 |
| 52-Week Range | 107.34 - 161.56 |
| Beta | 1.22 |
| RSI | 46.51 |
| Earnings Date | May 27, 2026 |
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnosti... [Read more]
Financial Performance
In fiscal year 2025, Agilent Technologies's revenue was $6.95 billion, an increase of 6.73% compared to the previous year's $6.51 billion. Earnings were $1.30 billion, an increase of 1.09%.
Financial numbers in USD Financial StatementsNews
Agilent to Participate in Jefferies Global Healthcare Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global He...
Agilent appoints Michael Buckner as CLO
Agilent Technologies (A) announced the appointment of Michael Buckner as chief legal officer. Buckner joins Agilent from Danaher Corp. (DHR), where he served as vice president, deputy general counsel,...
Agilent Names Michael Buckner as Chief Legal Officer
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Bu...
Agilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2026 after the stock mark...
Labcorp announces availability of Agilent’s PD-L1 IHC 22C3 pharmDx
Labcorp (LH) announced the nationwide availability of Agilent Technologies’ (A) PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. FDA to identify patients with platinum-resist...
Axion BioSystems and Agilent Technologies Resolve Litigation
ATLANTA--(BUSINESS WIRE)--Axion BioSystems, Inc., a leading provider of live-cell analysis technologies, today announced that Agilent Technologies, Inc. and Axion BioSystems have fully resolved the is...
Agilent showcases cancer research solutions at AACR 2026
Agilent (A) Technologies will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research A...
Agilent Showcases Cancer Research Solutions at AACR 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics ...
Agilent price target lowered to $140 from $150 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Agilent (A) to $140 from $150 and keeps an Overweight rating on the shares. The firm adjusted targets in the…
Agilent price target lowered to $140 from $160 at Evercore ISI
Evercore ISI lowered the firm’s price target on Agilent (A) to $140 from $160 and keeps an Outperform rating on the shares as part of the firm’s medical technology and…
Agilent announces BioTek Cytation 9 cell imaging multimode reader
Agilent (A) Technologies announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-cont...
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfo...
Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
Agilent Technologies (A) announced that it has received U.S. Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients…
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, ...
Agilent upgraded to Buy from Hold at Nephron Research
Nephron Research analyst Jack Meehan upgraded Agilent (A) to Buy from Hold with a $145 price target
Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United S...
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development an...
Citi opens ‘upside 90-day catalyst watch’ on Agilent
Citi opened an “upside 90-day catalyst watch” on shares of Agilent (A) while keeping a Buy rating on the name with a $185 price target The share overhang of a…
Agilent to acquire Biocare Medical for $950M in cash
Agilent (A) announced it has entered into a definitive agreement to acquire Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners, in an all-cash transaction…
M&A News: Agilent to Buy Biocare Medical for $950M — What Investors Should Know
Agilent Technologies ($A) announced that it will acquire Biocare Medical in a $950 million all-cash deal, aiming to strengthen its position in the fast-growing pathology and cancer diagnostics market....
Agilent to acquire Biocare Medical in $950 million all-cash deal
Life sciences firm Agilent Technologies said on Monday that it will acquire clinical pathology firm Biocare Medical in an all-cash deal valued at $950 million.
Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies
Denver, CO and London, UK, 9 March 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, GHO Capital Partners L...
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire ...
Agilent Technologies Transcript: TD Cowen 46th Annual Health Care Conference
Management reported strong growth in key markets, driven by innovation and favorable industry trends. Guidance for the year remains intact, with disciplined capital allocation and ongoing investments in digital, AI, and capacity expansion. Margin expansion and free cash flow are on track, supported by robust demand and prudent risk management.
Agilent price target lowered to $160 from $180 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Agilent (A) to $160 from $180 and keeps an Overweight rating on the shares. The firm updated its model…